Monoclonal antibody against interleukin-13 receptor alpha 1 (IL-13Ra1)
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Aug 31, 2010
Grant Date -
Mar 17, 2005
app pub date -
May 20, 2004
filing date -
Mar 22, 2002
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention relates generally to antibodies that bind to the Interleukin-13 receptor α1 chain (IL-13Rα1) and antagonize IL-13 receptor-mediated signaling by IL-13 and/or IL-4. More particularly, the present invention provides humanized or human antibodies to mammalian and in particular IL-13Rα1. These antibodies have uses in the treatment or prevention of IL-13- and/or IL-4-mediated diseases or conditions. The present invention further contemplates a method of modulating IL-13- and/or IL-4-mediated diseases or conditions by the administration of the subject antibodies. The present invention further provides an assay system useful for identifying antibodies or other agents which modulate IL-13 and/or IL-4 signaling through an IL-13 receptor complex. Accordingly, a method of screening for modulators of IL-13Rα1/ligand interaction is also provided.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully